Skip to main content

Table 1 Baseline characteristics of patients

From: Predictive significance of arachidonate 15-lipoxygenase for eosinophilic chronic rhinosinusitis with nasal polyps

 

ECRSwNP (n = 30)

NonECRSwNP (n = 18)

P value

Demographic characteristics

 Sex, male/female

17/13

11/7

0.762

 Age, y (mean ± SD)

45.03 ± 11.86

46.00 ± 15.77

0.810

 Previous surgery, n (%)

10 (33.33)

7 (38.89)

0.697

 Asthma, n (%)

16 (53.33)

2 (11.11)

0.003

 Allergic rhinitis, n (%)

9 (30.00)

1 (5.56)

0.044

 Atopy, n (%)

16 (53.33)

4 (22.22)

0.034

Histopathological findings (H&E staining)

 Tissue eosinophils (%), median (IQR)

57.27 (41.86–68.43)

4.19 (1.97–6.68)

 < 0.001

 Tissue neutrophils (%), median (IQR)

0.00 (0.00–2.18)

6.84 (2.53–13.39)

0.003

Self-assessed symptom scores (VAS)

 Nasal obstruction score, median (IQR)

7.00 (6.00–8.00)

6.00 (6.00–8.00)

0.572

 Rhinorrhea score, median (IQR)

6.00 (5.00–7.00)

5.50 (0.00–6.00)

0.078

 Olfaction score, median (IQR)

9.00 (6.00–10.00)

6.00 (4.00–8.00)

0.002

 Facial pain or headache score, median (IQR)

0.00 (0.00–5.00)

0.00 (0.00–5.25)

0.581

 Total VAS score, median (IQR)

22.50 (19.00–25.50)

19.50 (16.75–22.25)

0.021

Imaging examination scores

 CT score, median (IQR)

17.50 (14.00–22.00)

17.50 (11.00–20.25)

0.326

 E/M ratio, median (IQR)

2.33 (2.00–3.50)

2.00 (2.00–2.00)

0.003

 Endoscopy score, median (IQR)

5.50 (4.00–7.00)

4.00 (2.75–5.00)

0.003

Routine blood tests

 Blood eosinophils (%), median (IQR)

6.25 (5.05–9.20)

1.60 (0.78–4.95)

 < 0.001

 Blood neutrophils (%), median (IQR)

53.45 (47.03–56.68)

58.50 (48.18–69.75)

0.058

  1. ECRSwNP eosinophilic chronic rhinosinusitis with nasal polyps, nonECRSwNP non-eosinophilic chronic rhinosinusitis with nasal polyps, y years, SD standard deviation, n number, H&E hematoxylin and eosin, IQR interquartile range, VAS visual analogue scale, CT computed tomography, E/M ethmoid/maxillary sinus. Italic values are significant at P < 0.05